X4 Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The 4WARD trial targets enrollment completion by year-end 2026 and topline data in Q1 2028, following a sample-size reduction and improved enrollment operations. Management outlined a 15,000-30,000-patient opportunity, a G-CSF tapering study, and funding into 2029.
-
The pivotal 4WARD trial remained on track to finish enrollment by year-end 2026, with top-line results expected by the end of Q1 2028. Management sees a 15,000–30,000-patient opportunity and said $188M in cash supports commercialization.
-
4WARD enrollment is expected to finish in Q4 2026, with top-line data in Q1 2028; positive results could support approval in late 2028 or early 2029. Market research points to a 15,000-patient initial PCN opportunity, potentially extending to 30,000, and cash runway into 2029.
-
Mavorixafor's phase III trial for chronic neutropenia is on track with a reduced enrollment target and strong FDA alignment. Operational changes have improved enrollment, and a new study will address G-CSF reduction. Commercial launch is targeted for late 2028 or early 2029.
-
Significant restructuring and capital raises have positioned the company to advance mavorixafor, an oral therapy for chronic neutropenia, through a pivotal phase III trial with data expected in 2027 and potential FDA approval in 2028. The company targets a 15,000-patient U.S. market and plans to explore additional indications after 2028.
-
Management overhaul and strategic refocus have streamlined operations and prioritized the 4WARD Phase III trial in chronic neutropenia, targeting a 2028 launch. Mavorixafor's oral formulation and favorable safety profile position it to address unmet needs in a 15,000-patient U.S. market.
-
Leadership has streamlined operations to focus on mavorixafor for chronic neutropenia, with a pivotal Phase III trial underway and enrollment targeted for completion by Q3. The therapy addresses significant unmet needs, offers an oral alternative to G-CSF, and has shown promising efficacy and safety data.
Fiscal Year 2025
-
A new management team has restructured operations, focusing on the 4WARD phase III trial for mavorixafor in chronic neutropenia, a market estimated at 15,000 US patients. The trial aims for top-line data in H2 2027, with commercialization targeted for 2028 and a premium pricing strategy.
-
Q1 2025 saw strong clinical and commercial progress, with XOLREMDI sales reaching $3.5M and robust advancement in the 4WARD phase III CN trial. Cash reserves support operations into 2026, and new global partnerships and a U.S. patent strengthen future prospects.
Fiscal Year 2024
-
Achieved U.S. launch of XOLREMDI for WHIM syndrome, with $2.6M in 2024 sales and strong physician engagement. Expanded globally via partnerships and EMA review, while focusing on chronic neutropenia and reducing costs. Cash position supports operations into 2026.
-
FDA approval of Xolremdy for WHIM syndrome marks a major milestone, with robust clinical data supporting its efficacy and safety. Expansion into chronic neutropenia and international markets is underway, with strong financial resources supporting key milestones through 2025.
-
FDA approval and commercial launch of XOLREMDI have driven increased physician awareness and patient onboarding, with reimbursement and payer coverage expanding. Robust Phase 2 data in chronic neutropenia supports ongoing Phase 3 trials, and international expansion is planned for 2025.
-
Positive Phase II results for mavorixafor in chronic neutropenia showed durable ANC increases and significant G-CSF dose reductions, supporting advancement to a global Phase III trial. XOLREMDI launch for WHIM syndrome is progressing, with strong physician engagement and favorable reimbursement.
-
Significant progress was highlighted, including the approval and launch of XOLREMDI for WHIM syndrome, strong clinical data in chronic neutropenia, and a robust commercial strategy. Upcoming catalysts include a European MAA filing and final phase II CN data in November.
-
Xolremdi, the first oral CXCR4 antagonist, was approved for WHIM syndrome, showing strong efficacy in reducing infections. Expansion into chronic neutropenia is underway, with promising phase II data and a pivotal phase III trial targeting high unmet need patients. Robust IP and financial strategies support continued growth.
-
US approval and launch of XOLREMDI for WHIM syndrome drove strong initial sales and positive reimbursement outcomes. Monetization of a priority review voucher boosted Q2 net income to $90.8 million, with a cash runway into late 2025. Positive clinical progress in chronic neutropenia supports future growth.
-
Interim Phase 2 results show mavorixafor, an oral CXCR4 antagonist, durably increases neutrophil counts in chronic neutropenia patients, both as monotherapy and with G-CSF, with a favorable safety profile. All evaluable patients achieved meaningful ANC increases, supporting rapid advancement to Phase 3. Full data, including dose-adjusted G-CSF subgroup, is expected later this year.